GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » Debt-to-Revenue

Arovella Therapeutics (FRA:E4NA) Debt-to-Revenue : 0.00 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Arovella Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Arovella Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €0.00 Mil. Arovella Therapeutics's annualized Revenue for the quarter that ended in Jun. 2024 was €0.01 Mil. Arovella Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.00.


Arovella Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Arovella Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Debt-to-Revenue Chart

Arovella Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.31 0.49 - -

Arovella Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.05 - - -

Competitive Comparison of Arovella Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Arovella Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arovella Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's Debt-to-Revenue falls into.



Arovella Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Arovella Therapeutics's Debt-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as

Arovella Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


Arovella Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Arovella Therapeutics Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton, WA, AUS, 3053
Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics Headlines

No Headlines